125 related articles for article (PubMed ID: 37863284)
21. Differentiation of the Follicular Variant of Papillary Thyroid Carcinoma From Classic Papillary Thyroid Carcinoma: An Ultrasound Analysis and Complement to Fine-Needle Aspiration Cytology.
Ng SC; Kuo SF; Hua CC; Huang BY; Chiang KC; Chu YY; Hsueh C; Lin JD
J Ultrasound Med; 2018 Mar; 37(3):667-674. PubMed ID: 28880405
[TBL] [Abstract][Full Text] [Related]
22. Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology.
Wang Y; Song W; Li Y; Liu Z; Zhao K; Jia L; Wang X; Jiang R; Tian Y; He X
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16837-16850. PubMed ID: 37733241
[TBL] [Abstract][Full Text] [Related]
23. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
24. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma.
Zhang S; Wang Y; Chen M; Sun L; Han J; Elena VK; Qiao H
Sci Rep; 2017 Mar; 7():44033. PubMed ID: 28272462
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W
Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
[TBL] [Abstract][Full Text] [Related]
27. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.
Tunca F; Sormaz IC; Iscan Y; Senyurek YG; Terzioglu T
J Endocrinol Invest; 2015 Dec; 38(12):1327-34. PubMed ID: 26280320
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma.
Attia AS; Hussein S; Sameh H; Khalil A; Waley AB; Matar I; Sameh R
Cancer Biomark; 2024; 39(3):211-221. PubMed ID: 38073379
[TBL] [Abstract][Full Text] [Related]
29. Highly accurate diagnosis of papillary thyroid carcinomas based on personalized pathways coupled with machine learning.
Park KS; Kim SH; Oh JH; Kim SY
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33341874
[TBL] [Abstract][Full Text] [Related]
30. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
31. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
32. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
[No Abstract] [Full Text] [Related]
34. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules.
Li XJ; Mao XD; Chen GF; Wang QF; Chu XQ; Hu X; Ding WB; Zeng Z; Wang JH; Xu SH; Liu C
Medicine (Baltimore); 2019 Jul; 98(28):e16343. PubMed ID: 31305422
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
36. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.
Genpeng L; Jianyong L; Jiaying Y; Ke J; Zhihui L; Rixiang G; Lihan Z; Jingqiang Z
Medicine (Baltimore); 2018 Feb; 97(5):e9619. PubMed ID: 29384841
[TBL] [Abstract][Full Text] [Related]
37. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of Cyclin D1 and P21 in the differential diagnosis of papillary thyroid carcinoma.
Wang CC; Lu DD; Shen MH; Chen RL; Zhang ZH; Lv JH
Diagn Pathol; 2023 Nov; 18(1):123. PubMed ID: 37951919
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
40. Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.
Geropoulos G; Psarras K; Papaioannou M; Giannis D; Meitanidou M; Kapriniotis K; Symeonidis N; Pavlidis ET; Pavlidis TE; Sapalidis K; Ahmed NM; Abdel-Aziz TE; Eddama MMR
In Vivo; 2022; 36(4):1551-1569. PubMed ID: 35738604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]